The Implications of 9th Lung Cancer TNM Classification on Interventional Pulmonology

🩺 Clinical Context

The 9th edition of the TNM classification, effective January 2025, introduces granular changes to N and M descriptors that directly impact staging and therapeutic decision-making. For the Interventional Pulmonologist, the subdivision of N2 into N2a (single station) and N2b (multiple stations) necessitates a shift toward more precise, systematic mediastinal sampling to avoid under-staging, which now carries significant prognostic and treatment-allocation implications.

📊 Methodological Strengths & Weaknesses

💡 Takeaway for Fellows

1. Precision Matters: With the N2a/N2b split, your staging report must explicitly document the specific nodal stations sampled. 2. Contamination Risk: Be aware that the majority of practitioners do not change needles between N2 stations, yet the clinical impact of potential cross-contamination remains an open question—await results from NCT07418450. 3. Technological Evolution: While conventional EBUS remains the gold standard, thin convex-probe EBUS and robotic-assisted platforms are expanding our reach into subsegmental (N1) and peripheral (stations 5/6) nodes, which may soon become part of routine staging. 4. Molecular Yield: Prioritize cryo-EBUS or high-quality core acquisition when molecular profiling is the primary goal, especially in never-smokers.